Public Consultation on the Post-market Review of Ezetimibe

Page last updated: 23 May 2017

Public Consultation: 23 May 2017 to 6 June 2017

The Department is now inviting submissions from interested stakeholders addressing the revised draft Report to the PBAC for this Review. The public submission process will be open for two weeks.  Submissions must be lodged by 5pm Tuesday, 6 June 2017.

Accessibility

The documents on this page may not be accessible. If you need assistance please email the Ezetimibe Review Secretariat.

Lodgement

To ensure the successful lodgement of your submission please follow these steps:

  1. Complete and attach the Ezetimibe Review Submission Cover Sheet to your submission.
  2. Limit your response to a maximum of four pages of text and two pages of tables.  The Department may not consider submissions that exceed this limit.
  3. Provide your submission in a Microsoft Word or PDF format.
  4. Please email your comments to the Ezetimibe Review Secretariat before 5pm on Tuesday, 6 June 2017.

Revised Draft Ezetimibe Post-market Review Report to the PBAC and Revised appendix E:

Public Submissions addressing Draft Ezetimibe Post-market Review Report to the Pharmaceutical Benefits Advisory Committee (PBAC): 30 January 2017 to 10 February 2017 (closed)

The Call for Submissions addressing the draft review report closed on 10 February 2017.  The Department appreciates the contribution of all organisations and individuals who made a submission.

Submissions addressing the Stakeholder Forum Outcome Statement: 23 November to 25 November 2016 (closed)

The Call for Submissions addressing the Stakeholder Forum Outcome Statement was extended to those who attended the Forum. The Department appreciates the contribution of all stakeholders who made a submission.

Public Submissions addressing Terms of Reference: 4 March to 22 April 2016 (closed)

The Call for Submissions addressing the Terms of Reference closed on 22 April 2016.  The Department appreciates the contribution of all organisations and the individual who made a submission.

Public Submissions on draft Terms of Reference: 16 October to 13 November 2015 (closed)

The Call for Submissions on the draft Terms of Reference closed on 13 November 2015.  The Department appreciates the contribution of all organisations and individuals who made a submission.

Subscribe to news updates for the latest information regarding reviews, including public consultation opportunities.

Disclaimer

  • The views expressed in submissions published on this website are solely those of the contributing authors or organisations.
  • The Commonwealth accepts no responsibility for the completeness or accuracy of any information contained in the submissions.
  • The Commonwealth makes no representations about the suitability of the information for any particular purpose. Users of the information must make their own inquiries and assessments about those matters or seek independent advice.
  • Submissions are published on the understanding that the contributing authors or organisations have copyright in the submissions either by way of ownership or a licence. They retain their copyright, and by making submissions they licence the Commonwealth to publish the submissions, unless a party when making a submission has requested that it be kept confidential and the Commonwealth clearly agrees that the submission will be kept confidential.

Privacy

Unless otherwise requested, submissions addressing the Post-market Review of Ezetimibe have been published below.

The Department of Health does not publish submissions, or parts of submissions, which contain personal information, offensive language, potentially defamatory material or copyright infringing material.

Responsibility for copyright in submissions resides with the author(s), not with the Department of Health.

All submissions have been converted to Portable Document Format (PDF) for publication and may have a different appearance to the document that was submitted.

Your submission and contact details will be stored in accordance with the Australian Privacy Principles from Schedule 1 of the Privacy Amendment (Enhancing Privacy Principles) Act 2012 and the Archives Act 2012.  Should you have any concerns about the storage of your submission, or if you wish to gain access to make a correction, please contact the Ezetimibe Review Secretariat. A copy of the Department’s privacy policy is available on request. If you wish to make a complaint about the handling of your private information, you may contact the Department of Health Privacy Contact Officer on 02 6289 5773 and, if unsatisfied with the response, you may submit a complaint to the Office of the Australian Information Commissioner.

Table of Submissions addressing Stakeholder Forum Outcome Statement

Table of Submissions addressing Outcome Statement

Submission

Author Name

Document Link

Date Received

1

The Pharmacy Guild of Australia

Submission 1

23/11/2016

2

Professor Paul Nestel, Alfred Hospital Melbourne

Submission 2

25/11/2016

3

Professor David Hare, University of Melbourne

Submission 3

25/11/2016

4

Research Organisation

Not for publication

25/11/2016

5

MSD

Submission 5

25/11/2016

6

Industry Organisation

Not for publication

01/12/2016

Table of Submissions addressing Terms of Reference

Table of Submissions addressing Terms of Reference

Submission

Author Name

Document Link

Date Received

1

Council of Australian Therapeutic Advisory Groups (CATAG)

Submission F1

20/04/2016

2

Assoc. Prof. John Amerena

Submission F2

21/04/2016

3

Amgen Australia Pty Ltd

Submission F3

22/04/2016

4

Sanofi

Submission F4

22/04/2016

5

Merck Sharp & Dohme (Australia) Pty Limited

Submission F5

22/04/2016

6

Medicines Australia

Submission F6

22/04/2016

Table of Submissions addressing draft Terms of Reference

Table of Submissions addressing draft Terms of Reference

Submission

Author Name

Document Link

Date Received

1

Academic/ Health professional

Not for publication

30/10/2015

2

Prof. Paul Nestel

Submission D2

5/11/2015

3

Academic/ Health professional

Not for publication

5/11/2015

4

Merck Sharpe & Dohme (Australia) Pty Limited

Submission D4

13/11/2015

5

Medicines Australia

Submission D5

13/11/2015

6

Kidney Health Australia

Submission D6

16/11/2015